Jeanne Freddura
Corporate Officer/Principal at COMMUNITY REDEVELOPMENT INC.
Profile
Jeanne Freddura is currently the Senior Vice President-Finance & Development at Community Redevelopment, Inc. Her former job was as a Controller at Syntimmune, Inc. She has a graduate degree from Harvard University and an undergraduate degree from Cambridge College.
Jeanne Freddura active positions
| Companies | Position | Start |
|---|---|---|
| COMMUNITY REDEVELOPMENT INC. | Corporate Officer/Principal | 02/02/2022 |
Former positions of Jeanne Freddura
| Companies | Position | End |
|---|---|---|
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Comptroller/Controller/Auditor | - |
Training of Jeanne Freddura
| Harvard University | Graduate Degree |
| Cambridge College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| COMMUNITY REDEVELOPMENT INC. | Finance |
| Private companies | 1 |
|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Jeanne Freddura